Abstract
Tanagho and Schmidt working in the 1980s developed sacral neuromodulation (SNM). The FDA approved InterStim® for the treatment of urge incontinence in 1997, and NICE did the same in 2004. In many centers, SNM has become second-line treatment for idiopathic detrusor overactivity (IDO) and nonobstructive urinary retention in women (NOURW). There is limited evidence for its use in neurogenic bladder dysfunction and painful bladder disorders.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Further Reading
Bolton JF, Harrison SC. Neuromodulation 10 years on: how widely should we use this technique in bladder dysfunction? Curr Opin Urol. 2009;19(4):375–9.
Paniker J, DasGupta R, Elneil S, Fowler CJ. Urinary retention. In: Fowler CJ, Panicker JN, Emmanuel A, editors. Pelvic organ dysfunction in neurological disease. Cambridge: Cambridge University Press; 2010. p. 293–306.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer-Verlag London
About this chapter
Cite this chapter
Tawadros, C., Burnett, K.E., Betts, C.D. (2012). Neuromodulation by Sacral Nerve Stimulation. In: Payne, S., Eardley, I., O'Flynn, K. (eds) Imaging and Technology in Urology. Springer, London. https://doi.org/10.1007/978-1-4471-2422-1_68
Download citation
DOI: https://doi.org/10.1007/978-1-4471-2422-1_68
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-4471-2421-4
Online ISBN: 978-1-4471-2422-1
eBook Packages: MedicineMedicine (R0)